UCB Biosciences, Inc.
Clinical trials sponsored by UCB Biosciences, Inc., explained in plain language.
A subsidiary of UCB, a global biopharmaceutical company focused on neurology and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Rare disease drug now available through expanded access
Disease control Expanded accessThis program provides access to two experimental drugs, doxecitine and doxribtimine, for people with thymine kinase 2 deficiency (TK2d), a rare genetic disorder that can cause severe muscle weakness and early death. It is for children and adults who have a confirmed TK2 gene muta…
Sponsor: UCB BIOSCIENCES, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can a Weight-Loss drug ease rett syndrome?
Symptom relief Recruiting nowThis Phase 3 trial tests whether fenfluramine (Fintepla) can reduce behavioral and emotional symptoms in people with Rett syndrome. About 200 participants will receive either the drug or a placebo for 14 weeks. The study measures changes in behavior, sleep, and overall condition …
Phase 3 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC